Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma

Postscriptum From the T-Dis Trial

Penel, Nicolas MD, PhD*,†; Decoupigny, Emilie MSc; Tresch-Bruneel, Emmanuelle MSc; Le Cesne, Axel MD§; Taieb, Sophie MD; Isambert, Nicolas MD, PhD

American Journal of Clinical Oncology: September 2019 - Volume 42 - Issue 9 - p 737
doi: 10.1097/COC.0000000000000576
Letter to the Editor

Departments of *Medical Oncology

Clinical Research and Innovation

Radiology, Centre Oscar Lambret

Lille University, Lille

§Department of Medical Oncology, Gustave Roussy, Villejuif

Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France

T-Dis trial was supported through competitive national research (PHRC) grant from the National Cancer Institute of France (INCa) ( PharmaMar, S.A. had supplied the drug for the randomized part of the trial. PharmaMar, S.A. had no role in study design, collection, analysis, or interpretation of data. The corresponding author had full access to all of the data and the final responsibility to submit for publication.

The authors declare no conflicts of interest.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.